Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study

Table 3 Results of main clinical outcomes after CAR-T

Group	1-year cumulative incidence of relapse (%)	2-year cumulative incidence of relapse (%)	1-year LFS (%)	2-year LFS (%)	1-year OS (%)	2-year OS (%)
Non-transplant	55.3	67.2	44.7	32.8	59.1	36.4
MRD+	38.2	65.8	55.2	27.6	62.7	62.7
MRD−	8.4	17.3	91.6	76.1	94.3	83.3
P between non-transplant and MRD+		0.139		0.305		0.231
P between non-transplant and MRD−		< 0.001		< 0.001		< 0.001
P between MRD+ and MRD−		0.006		0.007		0.069

ISSN: 1756-8722